Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Erasca (NASDAQ: ERAS ) is a precision oncology company, which means it focuses on therapies that target very specific cancer-related mutations. In particular, the main pathways it uses are the RAS/MAPK pathways. ERAS has a relatively late-stage pipeline with Naporafenib, whichMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, ...